Research programme: KRAS G12D protein inhibitors - Erasca
Alternative Names: ERAS-4; KRAS G12D inhibitors - Erasca; KRAS G12D protein inhibitors - ErascaLatest Information Update: 09 May 2023
At a glance
- Originator Erasca
- Class Antineoplastics; Small molecules
- Mechanism of Action KRAS protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 31 Dec 2022 Erasca has a patent pending for KRAS G12D inhibitors, their preparation and method of use
- 31 Dec 2022 Erasca has worldwide protection for patent family relating to KRAS G12D inhibitors, their preparation and method of use
- 12 Oct 2022 Preclinical trials in Solid tumours in USA (unspecified route) as of October 2022